MicroViable Therapeutics is a science-based biotech, born in 2016 as a startup from the Spanish National Research Council (CSIC) and located in the beautiful area of Gijón (Asturias, Spain).

Our goal is to develop next generation biotherapeutics based on complex communities from the intestinal microbiota. The microbiota-based therapeutics can be implemented as adjuvants in certain disease where a microbiota dysbiosis (alteration) exist. Examples of this dysbiosis occurred in antibiotic-associated diarrhea, inflammatory bowel disease (IBD), cancer treatments and Clostridium difficile infection.

Our team

Microviable Therapeutics has assembled an experienced team of leaders in intestinal microbiota, probiotics and human health, and biotech business development to drive our technology into tangible products and clinic development.

Claudio Hidalgo Cantabrana, PhD
Chief Executive Officer and co-founder
Rafael Martinez Permuy, MBA
Chief Business Officer and co-founder
Noelia Martínez, PhD
Chief Technological Officer and co-founder
Abelardo Margolles, PhD
Scientific Advisor and co-founder
Professor at IPLA-CSIC
Susana Delgado, PhD
Scientific Advisor and co-founder
Principal Investigator at IPLA-CSIC
Borja Sánchez, PhD
Scientific Advisor and co-founder
Principal Investigator at IPLA-CSIC

We are thankful and grateful to PadeInvest and the private investors for their support.

Subsidized project